Home > Insider Trading > Filing (0000899243-20-003364)

Filing Details

Accession Number:: 0000899243-20-003364
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-05 17:59:28
Reporting Period:: 2020-02-03

Accepted Time:: 2020-02-05 17:59:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701541	Black Diamond Therapeutics Inc.	BDTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1354345	Phd J Bradley Bolzon	C/O Black Diamond Therapeutics, Inc. 139 Main Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-03	4,973,787	$0.00	5,305,372	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	380,817	$0.00	380,817	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	1,277,111	$0.00	1,277,111	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	653,412	$0.00	5,958,784	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	150,085	$0.00	530,902	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	503,327	$0.00	1,780,438	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	810,522	$0.00	810,522	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	454,548	$0.00	6,413,332	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	104,407	$0.00	635,309	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	350,141	$0.00	2,130,579	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	79,013	$19.00	2,209,592	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	23,560	$19.00	658,869	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	396,082	$19.00	6,809,414	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	396,081	$19.00	1,206,603	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-02-03	15,000,000	$0.00	4,973,787	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-02-03	1,148,474	$0.00	380,817	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-02-03	3,851,526	$0.00	1,277,111	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	1,970,572	$0.00	653,412	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	452,630	$0.00	150,085	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	1,517,940	$0.00	503,327	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	2,444,382	$0.00	810,522	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	1,370,833	$0.00	454,548	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	314,873	$0.00	104,407	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	1,055,960	$0.00	350,141	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose.
Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date.
Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16.
Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16.
Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.
Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date.
Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). The Reporting Person may be deemed to beneficially own indirectly 810,522 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16.
On February 3, 2020, Versant Voyageurs I purchased 79,013 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On February 3, 2020, Versant I Parallel purchased 23,560 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On February 3, 2020, Versant VI purchased 396,082 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On February 3, 2020, Versant Vantage I purchased 396,081 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.